EFFECT OF CIPROFIBRATE ON PLATELET-AGGREGATION IN PATIENTS WITH COMBINED HYPERLIPIDEMIA

This study was designed to investigate the effect of ciprofibrate on p latelet aggregation in patients with combined hyperlipidaemia, Platele t aggregation measurements in platelet-rich plasma were carried out in 30 patients using the Biola 230 LA platelet aggregation analyser befo re treatment, 4 weeks and 8 weeks after ciprofibrate (100 mg/day) ther apy. A control group consisted of 37 healthy subjects. We found that s pontaneous and 0.25 mu M ADP-induced platelet aggregation were signifi cantly decreased after 4-weeks of therapy, from 4.6 to 3.2 % and from 11.3 to 7.6%, respectively. However, there was no difference 8 weeks a fter the treatment onset. Platelet aggregation induced by adrenaline w as unchanged during the ciprofibrate therapy.